IL1B and neoplasm: It has been shown that the ability of LPS, an inducer of IL-1β, to promote the growth of CT26 tumors strictly depends on functional NF-κB signaling, and that inhibition of NF-κB converts inflammation-induced tumor growth to TRAIL-mediated tumor regression [45].